Need professional-grade analysis? Visit stockanalysis.com
$579.16M
N/A
N/A
N/A
Kyverna Therapeutics, Inc. Common Stock (KYTX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $9.71, down 2.22% from the previous close.
Over the past year, KYTX has traded between a low of $2.01 and a high of $10.82. The stock has gained 355.9% over this period. It is currently 10.3% below its 52-week high.
Kyverna Therapeutics, Inc. Common Stock has a market capitalization of $579.16M.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Side-by-side comparison against top Healthcare peers.